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Introduction
There are a myriad of etiologies for patients presenting with acute hepatitis.
Nearly 10% of these cases are due to drug-induced liver injury (DILI).1 While
identifying the offending agent can be difficult, there are known offenders that can
be elucidated with an accurate history from the patient. However, in the nonnative patient or frequent international traveler, this can become a much more
challenging task given the medications, supplements and host of items used as
alternative medicines in other countries and cultures that may not be available in
the United States. While DILI is the most common cause of acute liver failure in
the United States, it is important to consider that the agent at play may not be
common to the United States.2 We aim to highlight the importance of using a
“global mindset” when treating international and frequent traveling patients, but
also demonstrate the severe hepatotoxic risks associated with Nimesulide.
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Case Presentation
We present a case of a 43 year-old female with comorbidities including iron
deficiency anemia, hyperlipidemia, and uterine leiomyomas that initially presented
to an outside hospital with chief complaint of abdominal pain. In addition, she
endorsed fevers, chills, arthralgias which progressed to also include dyspnea on
exertion, fatigue, dizziness, and non-bloody diarrhea. Her presenting labs revealed
significant liver injury (figures 1-3). Initial imaging with RUQ US showed gallbladder
wall thickening, hepatomegaly with diffuse fatty liver infiltrate. Subsequent CT A/P
w/o contrast showed similar findings, with concern for acute cholecystitis. General
surgery was consulted. HIDA scan was performed which did not show evidence of
acute cholecystitis. Her liver enzymes continued to worsen and thus MRI abdomen
w/wo contrast was ordered (fig. 4). The patient was transferred to Largo Medical
Center for further hepatology evaluation and the availability of interventional
endoscopic capabilities if warranted. On presentation to LMC, her pain was
improving though she felt her abdominal distention was worsening. During her initial
interview at LMC, she denied newly prescribed medications, OTC medications, or
use of herbal supplements. She reported she traveled to the Dominican Republic
where she spent 4 days and returned to the U.S. approximately 15 days prior to
initial presentation. The patient’s husband did have nausea, vomiting, and diarrhea
for a few days while on vacation, but it resolved spontaneously. Due to concerns for
infectious etiology, patient was treated with Zosyn and Doxycycline. She continued
to have MEG/RUQ abdominal pain, loose stool and nausea. Labs continued to
worsen. Extensive hereditary, autoimmune, vascular, inflammatory, infectious liver
serologies were completed which were unrevealing. Due to the unexplainable
etiology of liver injury, decision was made to proceed with liver biopsy. On the
morning of her liver biopsy, patient’s husband was present in the room during
morning interview and on further discussion with the couple, patient reported being
given medication for a headache while in the Dominican Republic. This medication
was discovered to be Nimesulide, of which she completed a pack of fifteen 100mg
tabs over the course of the proceeding week. Liver biopsy completed showing
histology c/w drug induced hepatitis (fig. 5). She was treated with supportive care
and conservative management and was able to be discharged with improvement in
her symptoms. On a follow-up visit 8 months later, she had complete normalization
in her liver enzymes and overall liver function.
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Microscopic description: mild to moderate perivenular hepatocyte degeneration and congestion associated
with lymphocytes and eosinophils, and intracellular cholestasis. Portal tracts show lymphocyte and eosinophil
infiltrates, and intracellular cholestasis. Portal tracts show lymphocyte and eosinophil infiltrates.

Conclusion
Figure 3

MRI w/wo contrast: Mild hepatomegaly. Findings compatible with hepatocellular
disease. Questionable gallbladder sludge and tiny stones. No significant inflammatory
change around the gallbladder. No biliary dilatation.
Figure 4
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Our patient experienced drug-induced hepatocellular liver injury attributed to
Nimesulide. Hepatocellular injury is the most common pattern of liver enzyme elevation
seen with Nimesulide, though cholestatic elevations have also been demonstrated.4
Nimesulide is predominantly a COX-2 inhibitor.4 There is no evidence that patients
sustaining DILI from Nimesulide will experience similar response to other non-steroidal
anti-inflammatory drugs.4 NSAIDs as a class do carry a risk of hepatotoxicity and this
appears to be highest with Nimesulide.3 Cases of fulminant liver failure requiring liver
transplantation and other cases ending in death related to Nimesulide have been
reported in the literature.4 Even more exist demonstrating transient, but significant, liver
injury.4 This case demonstrates the need for U.S. physician and patient awareness of
the hepatotoxic risks associated with Nimesulide.
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